1 – 50 of 102
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Cost-effectiveness of specialised manual therapy versus orthopaedic care for musculoskeletal disorders : long-term follow-up and health economic model
(
- Contribution to journal › Article
-
Mark
Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life
(
- Contribution to journal › Article
- 2021
-
Mark
Coronaviruset i Sverige. "Nedstängningar gör mer skada än nytta"
2021) In Svenska Dagbladet(
- Contribution to specialist publication or newspaper › Newspaper article
-
Mark
Projected economic burden of pancreatic cancer in Sweden in 2030
(
- Contribution to journal › Article
-
Mark
The Value of a New Diagnostic Test for Prostate Cancer : A Cost-Utility Analysis in Early Stage of Development
(
- Contribution to journal › Article
-
Mark
Swedish guidelines for device-aided therapies in Parkinson's disease —Economic evaluation and implementation
(
- Contribution to journal › Article
- 2019
-
Mark
Dread and Risk Elimination Premium for the Value of a Statistical Life
(
- Contribution to journal › Article
- 2018
-
Mark
Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype
(
- Contribution to journal › Article
- 2017
-
Mark
Acute biliary pancreatitis: focus on recurrence rate and costs when current guidelines are not complied
(
- Contribution to journal › Article
- 2016
-
Mark
Preferences for improvements in attributes associated with basal insulin : a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden
(
- Contribution to journal › Article
-
Mark
Dread and Risk Elimination Premium for the Value of a Statistical Life
2016) In Working Papers(
- Working paper/Preprint › Working paper
-
Mark
Measuring the End of Life Premium in Cancer using Individual ex ante Willingness to Pay
2016) In Working Papers(
- Working paper/Preprint › Working paper
-
Mark
Value of a QALY and VSI Estimated with the Chained Approach
(
- Working paper/Preprint › Working paper
-
Mark
Chained Approach vs Contingent Valuation for Estimating the Value of Risk Reduction
(
- Working paper/Preprint › Working paper
-
Mark
Betalningsviljan för att minska risken för icke-dödliga och dödliga skador i samband med vägtrafikolyckor – en pilotstudie med jämförelse av CV och kedje-ansats
2016) In IHE Rapport(
- Book/Report › Report
-
Mark
Betalningsviljan för att minska risken för icke-dödliga och dödliga skador i samband med vägtrafikolyckor – en studie med kedje-ansats
2016) In IHE Rapport(
- Book/Report › Report
-
Mark
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Value of treatment in clinical trials versus the real world : the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden
(
- Contribution to journal › Article
-
Mark
Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
(
- Contribution to journal › Article
-
Mark
Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe
(
- Contribution to journal › Article
- 2015
-
Mark
The End of the International Reference Pricing System?
2015) In Applied Health Economics and Health Policy(
- Contribution to journal › Article
-
Mark
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
(
- Contribution to journal › Article
-
Mark
Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
(
- Contribution to journal › Article
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
- 2014
-
Mark
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
(
- Contribution to journal › Article
-
Mark
Willingness to pay for a new drug delivery in Parkinson patients.
(
- Contribution to journal › Article
-
Mark
Costs and outcomes of an exercise referral programme - A 1-year follow-up study.
(
- Contribution to journal › Article
-
Mark
Obesity and Surgical Treatment - A Cost-Effectiveness Assessment for Sweden
(
- Contribution to journal › Article
-
Mark
Costs and Utilities of Manual Therapy and Orthopedic Standard Care for Low Prioritized Orthopedic Outpatients of Working Age: A Cost Consequence Analysis.
(
- Contribution to journal › Article
-
Mark
Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
(
- Contribution to journal › Article
- 2013
-
Mark
Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital.
(
- Contribution to journal › Article
-
Mark
Målriktad behandling av bröstcancer
2013)(
- Other contribution › Miscellaneous
-
Mark
A Candidate Gene Approach to ANCA-Associated Vasculitis Reveals Links to the C3 and CTLA-4 Genes but not to the IL1-Ra And Fcγ-RIIa Genes.
(
- Contribution to journal › Article
-
Mark
Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature.
(
- Contribution to journal › Article
-
Mark
Acute pancreatitis - costs for healthcare and loss of production.
(
- Contribution to journal › Article
-
Mark
Medicinska framsteg i behandling av kronisk myeloisk leukemi
2013)(
- Other contribution › Miscellaneous
- 2012
-
Mark
A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
(
- Contribution to journal › Article
-
Mark
Budget impact analysis of surgical treatment for obesity in sweden.
(
- Contribution to journal › Article
-
Mark
Drug and treatment costs in Parkinson's disease patients in Sweden.
(
- Contribution to journal › Article
-
Mark
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
(
- Contribution to journal › Article
-
Mark
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients
(
- Contribution to journal › Article
-
Mark
Hälsoekonomiska modeller vid diabetes: ett hjälpmedel för klinisk forskning och behandlingsval
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Societal Value of Stem Cell Therapy in Stroke - A Modeling Study.
(
- Contribution to journal › Article
- 2011
-
Mark
Missbrukets ekonomiska börda i Sverige
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Värdet av nya läkemedel: en förstudie
2011)(
- Contribution to conference › Paper, not in proceeding
-
Mark
Practical issues in handling data input and uncertainty in a budget impact analysis
(
- Contribution to journal › Article
-
Mark
Acquisition cost of dispensed drugs in individuals with multiple medications A register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis Productivity Gain Based on Direct Measurement of Work Capacity before and after 1 Year of Treatment
(
- Contribution to journal › Article
- 2010
-
Mark
The Value of Informal Caregiver Time for Psychotic Illness
(
- Contribution to journal › Article
-
Mark
Willingness to pay for health improvements of physical activity on prescription.
(
- Contribution to journal › Article